



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

1 SJCRH

**Reagent:** ☼ vv1009

**Catalog Number:** 2996

**Lot Number:**

**Provided:** 0.5 ml cell-free virus ( $5 \times 10^6$  pfu). Propagate on mammalian cell monolayers, using TK-cells in the presence of BUDR.

**Description:** A pSC11-based plasmid encoding a truncated IIIB-derived (B10) envelope gene was modified to remove the b-gal-coding fragment. The BH10 V1-V3 region was replaced with the corresponding sequence from a Memphis HIV-1 isolate (the remaining HIV-1 sequences derived from BH10). The substituted vector was recombined with vaccinia virus (WRwt) by disruption of the TK gene. A live virus was propagated on TK-143B cells in the presence of BUdR.

**Special Characteristics:** Virus is cytopathic. Virus expresses the HIV-1 envelope protein as a truncated product inclusive of external gp120 and gp41. The V1/V2 region has been partially sequenced (SWGSDKGEI KNCSFNITG IRDKVQKGYA YFYIPDIDQI NDNNDNTSY RLINCNT). Expression is driven by the P7.5 early/late promoter. The virus may be used for the elicitation and analysis of HIV-1 Env-specific immunity or the preparation of CTL target cells.  
Sterility: Negative for bacteria and mycoplasma.

**Recommended Storage:** Liquid nitrogen.

**Contributor:** Dr. Julia Hurwitz.

**References:** Slobod KS, Rencher SD, Farmer A, Smith FS, Hurwitz JL. HIV type 1 envelope sequence diversity in an inner city community. *AIDS Res Hum Retroviruses* **10**:873-875, 1994.  
Ryan KW, Ownes RJ, Hurwitz JL. Preparation and use of vaccinia virus vectors for HIV protein expression and immunization. In: *Immunology Methods Manual*, I Lefkovits (Ed), Academic Press 1995. Hallenberger S, Tucker SP, Owens RJ, Bernstein HB, Compans RW. Secretion of a truncated form of the human immunodeficiency virus type 1 envelope glycoprotein. *Virology* **193**:510-514, 1993.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**NOTE:**

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: vv1009 from Dr. Julia Hurwitz." Please include the references cited above in any publications.

**The US Government has submitted a patent application on the parent plasmid pSC11.**

**Scientists at for-profit institutions or who intend commercial use of this reagent must contact Dr. Sally Hu at the NIH Office of Technology Transfer, Email: [hus@mail.nih.gov](mailto:hus@mail.nih.gov), Phone: 301-435-5606, before the reagent can be released. Please specify the name and a description of the intended use of the reagent.**

**Last Updated:**

June 24, 2013

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.